Myotonic dystrophy (DM) is a genetic disorder caused by the expression (as RNA) of expanded CTG or CCTG repeats. The alternative splicing factor MBNL1 is sequestered to the expanded RNA repeats, resulting in missplicing of a subset of pre-mRNAs linked to symptoms found in DM patients. Current data suggest that if MBNL1 is released from sequestration, disease symptoms may be alleviated. We identified the small molecules pentamidine and neomycin B as compounds that disrupt MBNL1 binding to CUG repeats in vitro. We show in cell culture that pentamidine was able to reverse the missplicing of 2 pre-mRNAs affected in DM, whereas neomycin B had no effect. Pentamidine also significantly reduced the formation of ribonuclear foci in tissue culture cells, releasing MBNL1 from the foci in the treated cells. Furthermore, pentamidine partially rescued splicing defects of 2 pre-mRNAs in mice expressing expanded CUG repeats.
M yotonic dystrophy (DM) is an autosomal dominant genetic disorder that is characterized by a variety of symptoms.
There are 2 types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2). DM1 is linked to a (CTG) n repeat expansion in the 3Ј untranslated region of the DMPK gene, whereas DM2 is linked to a (CCTG) n repeat expansion in intron 1 of the ZNF9 gene. The current model is that the expanded repeats are toxic on the RNA level, where either repeat can form a stable structured RNA that aberrantly interacts with proteins in the nucleus (for review see refs. 1, 2).
One proposed molecular mechanism that may account for the disease symptoms is that, upon transcription of the expansions, either the CUG or CCUG repeats sequester RNA binding proteins from their normal cellular functions. The protein MBNL1 (Muscleblind-like 1) has been shown to bind both expanded CUG and CCUG repeats in vitro (3) (4) (5) , and colocalize with these expanded repeats in vivo (6) (7) (8) (9) (10) . MBNL1 is an alternative splicing factor and its sequestration leads to the missplicing of multiple pre-mRNAs in DM, which is thought to give rise to many of the symptoms of the disease. In support of this model, it has been shown that the disruption of the MBNL1 gene or expression of CUG repeats in mice causes symptoms and missplicing similar to those seen in DM patients (11) (12) (13) (14) . Furthermore, disease symptoms can be rescued and missplicing of many pre-mRNAs can be reversed in mice expressing CUG repeats by overexpression of MBNL1 (15) .
Aside from the overexpression of MBNL1, another possible approach to overcoming the sequestration of MBNL1 is to identify small molecules that specifically bind the CUG repeats and competitively release the sequestered MBNL1. As a step toward identifying a small molecule therapeutic for DM, a small library of molecules known to bind structured nucleic acid were screened for their ability to disrupt an MBNL1-CUG repeat interaction in vitro. Two molecules were identified that strongly disrupted the complex in vitro. Further testing showed that the molecule pentamidine was able to rescue missplicing of 4 tested pre-mRNAs in both cell culture and a mouse model of DM1.
Results

Identification of Small Molecules That Disrupt an MBNL1-CUG Repeat
Complex in Vitro. Twenty-six small molecules that are known to bind structured nucleic acid (Table S1 ) were screened to identify compounds that would disrupt a protein-RNA complex using a previously characterized MBNL1-CUG repeat gel shift assay (Fig. 1A ) (3) . The CUG RNA (CUG 4 ) used in this screen contains 4 repeats, which were stabilized into a stem-loop structure by using the ultrastable UUCG loop (Fig. 1 A) . The molecule that most effectively disrupted the complex was pentamidine, which competed with MBNL1 and disrupted the protein-RNA complex with an IC 50 of 58 Ϯ 5 M (Fig. 1 B-D) . Neomycin B was the next best molecule with an IC 50 of 280 Ϯ 40 M (Fig. 1 B-D) . The small molecules ethidium bromide and thiazole orange also disrupted the MBNL1-CUG 4 complex with an IC 50 in the 200-to 300-M range (Table  S1 ). However because of toxicity issues with ethidium bromide and thiazole orange, only pentamidine and neomycin B were chosen for further study to determine their ability to disrupt the MBNL1-CUG repeat interaction in vivo.
Pentamidine Rescues Missplicing in HeLa Cells of 2 Pre-mRNAs Misregulated in DM.
To determine whether either small molecule could rescue missplicing in cells, we investigated the alternative splicing of the insulin receptor (IR) and cardiac troponin T (cTNT) minigenes in HeLa cells, in the presence or absence of expanded CUG repeats. Both of these pre-mRNAs are misspliced in DM patients (3, (16) (17) (18) (19) (20) (21) (22) . MBNL1 represses inclusion of exon 5 in the cTNT pre-mRNA and binds directly upstream of exon 5 (3, 17) . MBNL1 positively regulates the inclusion of exon 11 of the IR pre-mRNA, but it is unknown whether MBNL1 directly binds this pre-mRNA (16) (17) (18) (19) 23) . It has been shown that the overexpression of 960 interrupted CUG repeats sequesters MBNL1 to foci containing the CUG repeats and ablates the regulation of multiple pre-mRNAs by MBNL1, including the regulation of these 2 minigene pre-mRNAs (3, 17, 19, 23) . A plasmid containing these 960 repeats can be transfected into HeLa cells, thus providing a cell-based model for studying the splicing defects of DM.
We observed that the addition of pentamidine was able to rescue the missplicing of both the cTNT and IR minigene pre-mRNAs caused by the expression of the expanded CUG repeats (Fig. 2  A-C) . For the IR pre-mRNA, the basal level of inclusion of exon 11 in HeLa cells is 97 Ϯ 1%, whereas cotransfection with the CUG repeat plasmid reduces inclusion to 73 Ϯ 1%. The missplicing was mostly rescued at 25 M pentamidine, returning exon 11 inclusion to 92 Ϯ 3% (Fig. 2 A and B) . Exon 11 levels were fully rescued to normal levels by 50 M pentamidine.
We next tested whether missplicing of the cTNT pre-mRNA could be rescued by pentamidine (Fig. 2C ). Exon 5 inclusion was seen to have a basal level of inclusion of 75 Ϯ 4% in HeLa cells, whereas cotransfection of CUG repeats raised it to 95 Ϯ 2%. Pentamidine also rescued this missplicing, although higher concentrations were required for rescue compared to the IR substrate. Inclusion of the cTNT exon 5 to normal levels was observed at 75 M pentamidine, whereas 50 M pentamidine showed a partial rescue, and 25 M pentamidine had no effect (Fig. 2C) . Unexpectedly, in the absence of CUG repeats, pentamidine was observed to reduce the inclusion of exon 5. We recently reported that MBNL1 competes with the essential splicing factor U2AF65 at the 3Ј end of intron 4 to block inclusion of the cTNT exon 5 (24) . MBNL1 binds a stem loop in this area and this interaction blocks U2AF65 binding in this region of the intron because U2AF65's single-stranded binding site is sequestered in the stem loop. We hypothesized that pentamidine was binding this stem loop and blocking U2AF65 binding through a mechanism similar to MBNL1 inhibition. Supporting this model we found that pentamidine competed with U2AF65 for binding to the 3Ј end of the intron (Fig.  S1 ). This result suggests that for the cTNT pre-mRNA both MBNL1 and pentamidine bind the same site to additively repress exon 5 inclusion in the absence of the CUG repeats, thus explaining the low levels of exon 5 inclusion in the absence of CUG repeats (Fig. 2C) . However, as the effect is less penetrant in the presence of CUG repeats, it appears that pentamidine is titrated to these repeats when they are present.
Because pentamidine was found to regulate cTNT exon 5 levels of inclusion in the absence of CUG repeats, we wanted to investigate whether pentamidine might generally affect splicing of other pre-mRNAs. We first tested its affect on the splicing of a highly expressed pre-mRNA from another minigene, as the previous pre-mRNAs tested were also from minigenes. The splicing of the PLEKHH2 pre-mRNA (that contains exons 20-22, all of which are constitutively included when endogenously expressed) was tested and found to be unaffected by the addition of either pentamidine or the expression of CUG repeats (Fig. 2D) . We next determined whether pentamidine affected the alternative splicing of endogenous pre-mRNAs in HeLa cells. None of the 4 alternatively spliced exons tested were affected by either the expression of the CUG repeats or the addition of 75 M pentamidine (Fig. 2E ). These results suggest that pentamidine does not globally affect either constitutive or alternative splicing, but only a subset of pre-mRNAs, which are MBNL1 dependent. Furthermore, it suggests that pentamidine does not affect either highly expressed pre-mRNAs (such as the PLEKHH2, which was expressed from a plasmid with a strong promoter), or the 4 endogenously expressed genes, which are likely to be expressed at much lower levels. Finally, it should be noted that transcript levels appeared relatively unchanged upon the addition of pentamidine for these pre-mRNAs. This indicates that pentamidine does not globally affect transcription or RNA turnover at the concentrations tested.
To determine whether neomycin B was able to rescue the missplicing induced by CUG repeat expression, it was also tested in the splicing assay described above. Neomycin B did not alter the splicing of either the cTNT or IR pre-mRNAs (Fig. S2 ). For the cTNT pre-mRNA, concentrations of 100 M and 200 M neomycin B were tested ( Fig. S2 A) ; for the IR pre-mRNA a single concentration of 500 M was tested (Fig. S2B) . These results indicate that neomycin B does not specifically bind the CUG repeats in this DM1 cell model, suggesting that neomycin B is likely binding other substrates in the cell.
Pentamidine Reduces CUG Repeat Foci Formation and Relieves MBNL1
Sequestration in HeLa Cells. To directly visualize pentamidine's effect on MBNL1 sequestration, CUG foci formation was investi- gated in the presence and absence of the small molecule. Using an anti-MBNL1 antibody, MBNL1 localizes to the nucleus of HeLa cells, without CUG repeats or pentamidine present ( Fig. 3 A-D) . Upon transfection with the CUG 960 plasmid, characteristic RNA ribonuclear foci were formed, which sequestered nearly all of the MBNL1 (Fig. 3 E-H) . Upon the addition of 75 M pentamidine, we observed that foci formation was decreased. We scored CUG transfected cells, with or without pentamidine, for foci formation. Cells were scored as either having foci or having no foci. Foci formation was reduced by 21% in the pentamidine-treated cells. Whereas this is not a full reduction, a 2 test gave a P value of 0.004, showing the difference between treated and untreated cells was significant. In cells treated with pentamidine where foci were eliminated, MBNL1 was found to be diffuse throughout the nucleus (Fig. 3 I-L) . This assay was also performed in HEK293 cells, which contain higher levels of endogenous MBNL1. In this cell line, foci formation was reduced 28% by treatment with 50 M pentamidine. A 2 test gave a P value of 0.5 ϫ 10 Ϫ40 , showing the difference between treated and untreated cells was also significant in this cell line.
Pentamidine Partially Rescues Missplicing of 2 Pre-mRNAs in a DM1
Mouse Model. We tested pentamidine's ability to rescue missplicing in a mouse model (HSA LR ) for DM1 in which 250 CUG repeats are expressed under an actin promoter (14) . Pentamidine was administered by i.p. injection in 2 dosage regimens, and missplicing of the chloride-1 (Clc-1) and Serca1 pre-mRNAs was assayed. Both of these pre-mRNAs are missplicing in DM; MBNL1 represses inclusion of exon 7a in the Clc-1 mRNA and enhances inclusion of exon 22 in the Serca1 mRNA (25) (26) (27) .
Adult mice normally have a Clc-1 exon 7a inclusion of 6 Ϯ 1%, whereas the HSA LR line has a level of 54 Ϯ 6%. Pentamidine treatment at a lower dosage (25 mg/kg twice a day) partially rescued inclusion to 37 Ϯ 3%, whereas a higher dosage regimen (40 mg/kg once a day) rescued splicing to 34 Ϯ 4% exclusion (Fig. 4 A and C) . When comparing the low dosage treatment to injection of only saline, the P value was Ͻ0.003 when using a Mann-Whitney U test. The P value for the high dosage treatment was Ͻ0.001. The number of mice used for each trial is noted in Fig. 4 C and D. Inclusion of the Serca1 exon 22 is normally 99.7 Ϯ 0.1% in adult mice, whereas HSA LR mice have drastically lower levels of 17 Ϯ 4%. Lower dosage pentamidine treatment minimally rescued exon 22 inclusion to 22 Ϯ 2%, whereas the higher dosage treatment more significantly rescued exon 22 inclusion to 36 Ϯ 4% (Fig. 4 B and D) . The P value for the lower dosage treatment regimen was Ͻ0.01, whereas the higher dosage regimen had a more significant P value that was Ͻ0.001. Further increases to the dosage regimens had substantial toxicity in the mice. An increase to 30 mg/kg twice daily was lethal, whereas dosages at or less than 25 mg/kg twice a day, or 40 mg/kg once a day were not. It is likely that higher levels of pentamidine could indeed further reverse the missplicing of these transcripts. However, this full rescue may not be achievable with pentamidine in HSA LR mice, because of the toxicity. Nonetheless, the partial rescue that was observed was statistically significant and strongly indicates that a small molecule can indeed work in a mammalian DM model to reverse missplicing.
Discussion
Many small molecules have been shown to bind and affect nucleic acid structure and function. Examples include aminoglycosides binding to specific sites in ribosomal RNA to inhibit various steps of translation or cisplatin crosslinking DNA to inhibit transcription and replication (28) (29) (30) . Dervan and colleagues have been quite successful in designing molecules that target specific sequences in DNA (31), but that technology does not exist for targeting specific RNA structures and sequences. Efforts are currently underway to understand the rules of small molecule-RNA interactions (32, 33) . To determine whether CUG repeats could be targeted by small molecules we screened a small library of known nucleic acid binding molecules and found that pentamidine and neomycin B bound CUG repeats and could displace MBNL1 in vitro. This limited screen of small molecules, plus recent screens by Gareiss and colleagues and Pushechnikov and colleagues with short peptides and peptoids (34, 35) , clearly demonstrate that CUG repeats can be targeted and that high throughput screens with large libraries of small molecules will almost certainly produce many additional lead compounds other than pentamidine for further studies. (36, 37) . Although pentamidine has been shown to bind to both DNA and RNA, the mechanism of its antifungal activity is unknown. Pentamidine may inhibit P. carinii growth by inhibiting the splicing of essential group I introns in this organism (38, 39) , although more recently pentamidine has also been shown to inhibit translation by binding tRNA (40) . It has also been proposed that pentamidine blocks DNA replication (37) , as a structure of pentamidine with DNA shows that it binds DNA in the minor groove (41) . Therefore it is likely that pentamidine interacts with many different nucleic acid targets within cells. Our results suggest pentamidine can, at least, partially target CUG repeats and release MBNL1. It is interesting to note that we previously showed that CUG repeats form an A-form structure, despite the U-U mismatches (42) ; although the minor grooves of A-form and B-form nucleic acid differ in architecture, it is tempting to speculate that pentamidine binds the minor groove of the A-form CUG repeats.
Pentamidine is currently used to treat Pneumocystis carinii infections (pneumonia) in acquired immunodeficiency syndrome (AIDS) patients and to treat patients with Trypanosomiasis and Leishmaniasis infections
The results with pentamidine are in contrast to neomycin B, which also disrupted the MBNL1-CUG repeat interaction in vitro (Fig. 1) , but did not rescue missplicing of any of the tested targets (Fig. S2) . Both pentamidine and neomycin B are known to bind many different nucleic targets, but only pentamidine displayed the ability to reverse the missplicing of 4 different pre-mRNAs affected by CUG repeats. These results suggest that pentamidine's sufficient specificity for CUG repeats has an effect in these assays, specificity that neomycin B apparently lacks.
The window of efficacy for pentamidine treatment in the DM1 cell culture and mouse model is narrow. Substantial cell death is observed in HeLa cells with pentamidine treatments of 100 to 125 ⌴. Raising the concentration of pentamidine for the mice treatments is also problematic because pentamidine dosages of 30 mg/kg twice a day are lethal to the mice, whereas 40 mg/kg once a day only partially relieves missplicing of the 2 tested pre-mRNAs (Fig. 4) . To overcome this toxicity, modifications to pentamidine will be performed to enhance the affinity and specificity of pentamidine for CUG repeats, thus allowing for a lower dosage treatment. One approach to improve pentamidine's affinity and specificity for CUG repeats will be to oligomerize pentamidine to obtain multivalent binding to the repeating CUGs. A multivalent strategy with a peptide backbone was recently used to obtain ligands that bind CUG and CCUG repeats with nanomolar affinity (34, 43) , supporting the idea that covalent linkage of multiple pentamidines might result in compounds with significantly better affinities to CUG repeats. Previous potential therapeutic approaches for DM1 have ranged from overexpression of MBNL1, RNA interference against the CUG repeats, CAG oligonucleotides that bind the CUG repeats and displace MBNL1, to targeted degradation of the mutant DMPK transcript with an RNA ribozyme (15, (44) (45) (46) (47) (48) . We have now demonstrated that releasing MBNL1 from the CUG repeats with a small molecule is another valid approach that should be considered for treating DM1.
Materials and Methods
MBNL1 Cloning and Purification. MBNL1 was PCR amplified and was cloned into GST fusion vector pGEX-6P-1 (Amersham), using DNA (MBNL1 isoform with amino acids 1-382) provided by Maury Swanson (17) . The MBNL1 (1-260) construct used in this study was cloned using BamHI and NotI restriction sites. Using BL21-Star expression cells (Invitrogen), protein expression was induced with 0.25 mM IPTG at an OD600 Ϸ0.5-1, for 3-4 h at 37°C. Cells were lysed in 30 mL of buffer [500 mM NaCl, 25 mM Tris pH 7.5, 10 mM ␤-Mercaptoethanol (BME) and 5% glycerol] using 1 mg/mL of lysozyme followed by sonication (3 ϫ 30 s) . Cell extract was centrifuged for 15 min at 17,000 rpm, and lysate which contained GST-MBNL1 was collected. GST-MBNL1 was bound to GST affinity beads for 30 min at 4°C. Beads were washed 5 times with buffer (1M NaCl, 25 mM Tris pH 7.5 and 5 mM BME); MBNL1 was cleaved from the affinity tag with Precision Protease (Amersham) and collected from the beads. The protein was then run over an anion exchange (Q) column. Copurifying contaminants bind the column, but MBNL1 does not. MBNL1 was collected in the column flow through, concentrated, and dialyzed into storage buffer (30% glycerol, 300 mM NaCl, 20 mM Tris pH 7.5, 5 mM BME) and stored at Ϫ80°C. Aliquots were removed from Ϫ80°C and temporarily placed in Ϫ20°C until used for an experiment.
RNA Labeling and Purification. All RNA substrates that were radiolabeled were ordered from IDT DNA, and 5Ј end-labeled using [␥-32 P]ATP and all RNAs were purified on an 8% denaturing acrylamide gel.
Gel Shift Assay. The final concentration in the reaction was 175 mM NaCl, 5 mM MgCl2, 20 mM Tris (pH 7.5), 12.5% glycerol, 2 mg/mL BSA and 0.1 mg/mL heparin. Before mixture with protein, RNA substrates were snap annealed (95°C for 1 min and then directly on ice for 20 min) in 66 mM NaCl, 6.7 mM MgCl2, and 27 mM Tris (pH 7.5). Protein and the small molecule were then added to the RNA. The binding reaction was in 10 L volume and was incubated for 10 min at room temperature (RT) before 2-4 L were loaded on a prechilled gel. RNA and RNA-protein complexes were separated on 3% acrylamide (37.5:1), 0.3% agarose (low melting point), 0.5ϫ Tris-Borate (TB) gels that were run for 2-3 h at 4°C, 25-50 volts. For U2AF65, a 6% acrylamide (37.5:1), 0.5ϫ TB was used and run at 175 volts, 4°C for 2 h. Gels were dried and autoradiographed. All small molecules were dissolved in water, ethanol, or ethanol/DMSO (50:50) according to manufacture's guidance for solubility.
For binding curves, the apparent Kd values were determined as previously described (3) . In brief, gels were quantified using ImageQuant (Molecular Dynamics). The percent RNA bound was determined by taking the ratio of RNA:protein complex to total RNA, per lane. Binding curves were graphed and apparent Kd values were determined with KaleidaGraph (Synergy) software using the following Eq. 1, where y ϭ % bound, m2 ϭ Kd, m1 ϭ total RNA concentration and m0 ϭ protein concentration.
This equation assumes a 1:1 interaction between the RNA and protein, which allows only an apparent Kd to be determined if the RNA contains more than 1 binding site. To determine the standard error of the apparent dissociation constants, 3-5 binding titrations were performed with each substrate and the apparent Kd values determined for each titration separately, before averaging. The error bars on the binding curve were obtained by averaging the individual titration points and calculating the standard deviation. Data points greater than 2 standard deviations from the average were discarded, with at least 3 data points remaining for standard deviation analysis.
To determine the IC50, Eq. 2 was used, where m0 ϭ small molecule concentration, m1 ϭ IC50, m2 ϭ Hill coefficient, and m3 ϭ fraction MBNL1 bound without small molecule present.
In Vivo Splicing. Splicing was performed as previously described (3). For full description, see SI Text.
Microscopy. HeLa or HEK294 cells were plated in 6-well plates onto coverslips. Cells were transfected with the normal protocol. For transfection, 500 ng of CUG 960 plasmid were transfected for each experiment. A total of 1 g of plasmid were transfected, with the additional amount being empty pcDNA3 vector. After transfection, pentamidine was added and the cells were fixed 16 h later. Cells were fixed for 15 min at RT with 4% PFA and washed 5 times for 10 min in 1ϫ PBS at RT. Cells were stored in 4°C, if not probed immediately. For the fluorescence in situ hybridization (FISH) procedure, cells were permeabilized with 0.5% triton X-100, in 1ϫ PBS at RT for 5 min. Cells were prewashed with 30% formamide, 2ϫ SSC for 10 min at RT. Cells were then probed for 2 h at 37°C, with a 1 ng/L of Cy3 CAG10 probe (IDT, IA) in 30% formamide, 2ϫ SSC, 2 g/mL BSA, 66 g/mL yeast tRNA, 2 mM vanadyl complex. Cells were then washed for 30 min The number of mice used for each sample is denoted as N. Using a Mann-Whitney U test, the significance of rescue for the low dosage compared to the saline treatment had a P value Ͻ0.003, whereas the high dose treatment had a P value Ͻ0.001. (D) Bar graph representation of partial rescue of Serca1 exon 21 splicing. The low dosage had a P value Ͻ0.01, whereas the high dosage had a P value Ͻ0.001.
in 30% formamide, 2ϫ SSC at 42°C, and then with 1ϫ SSC for 30 min at RT. Cells were next washed twice in 1ϫ PBS, 10 min at RT, and then probed overnight, at 4°C with anti-MBNL1 antibody (1:5000 dilution, A2764 antibody) in 1ϫ PBS. Cells were washed 2 times for 10 mins at RT with 1ϫ PBS. Next, cells were incubated with goat anti-rabbit Alexa 488 (1:500 dilution) for 2 h at RT. Cells were washed 2 times, for 10 mins at RT with 1ϫ PBS and then mounted onto glass slides using the hard-set mounting media that contains DAPI (Vectashield). Cells were imaged on an Olympus Fluoview FV1000 with a Bx61 scope. The number of cells scored was 254 for the CUG 960 transfection, and 193 cells were scored when cells were treated with pentamidine (75 M). A 2 test with 2 df was performed using Excel (Microsoft).
Treatment in Mice.
Mouse handling and experimental procedures were conducted in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care. HSA LR transgenic mice in line 20b were previously described (14) . These mice express human skeletal actin mRNA with Ϸ250 CUG repeats in the 3Ј-UTR. Age-and gender-matched HSA LR mice were injected i.p. with pentamidine or saline alone. For a low-dosage regimen, 25 mg/kg of pentamidine was administrated twice daily for 5 days. For a higher-dosage regimen, 40 mg/kg of pentamidine was injected once daily for 7 days. Mice were killed 1 day after the last injection, and vastus muscle was obtained for splicing analysis. RNA extraction and cDNA preparation were performed as described previously (49) . PCR amplification was carried out for 22-24 cycles with the following primer pairs: Clc1 forward: 5Ј-TGAAGGAATACCTCACACT-CAAGG-3Ј and reverse: 5Ј-CACGGAACACAAAGGCACTG-3Ј; Serca1 forward: 5Ј-GCTCATGGTCCTCAAGATCTCAC-3Ј and reverse: 5Ј-GGGTCAGTGCCT-CAGCTTTG-3Ј. The PCR products were analyzed on agarose gels and scanned with a laser fluorimager (Typhoon, GE Healthcare). Differences between 2 groups were evaluated by the Mann-Whitney U test.
